Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVA21 + Ipilimumab in Metastatic Uveal Melanoma
NCT03408587Phase 1Completed
- Sponsor
- Viralytics Ltd
- Start
- Jan 2018
- Primary completion
- May 2019
- Modality
- Oncolytic Viruses, Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of coxsackievirus a21 in Uveal melanoma (UM), sponsored by Viralytics Ltd. Primary endpoint: Incidence of treatment-related adverse events. Started Jan 2018; status: completed.
02
Drugs
coxsackievirus a21
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT03408587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03408587.